Cargando…

Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial

BACKGROUND: The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thu, Phuong Nguyen Thi, Huong, Minh Ngo Thị, Thi, Ngan Tran, Thanh, Hoi Nguyen, Minh, Khue Pham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480084/
https://www.ncbi.nlm.nih.gov/pubmed/34587911
http://dx.doi.org/10.1186/s12879-021-06687-3
_version_ 1784576399325003776
author Thu, Phuong Nguyen Thi
Huong, Minh Ngo Thị
Thi, Ngan Tran
Thanh, Hoi Nguyen
Minh, Khue Pham
author_facet Thu, Phuong Nguyen Thi
Huong, Minh Ngo Thị
Thi, Ngan Tran
Thanh, Hoi Nguyen
Minh, Khue Pham
author_sort Thu, Phuong Nguyen Thi
collection PubMed
description BACKGROUND: The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbiological efficacy of antibiotics on day 20 of treatment, we conducted an open-label randomized trial based on clinical outcomes, microbiological clearance, spirometry tests, and signs of systemic inflammation in patients hospitalized with acute exacerbations of COPD. METHODS: We enrolled 139 subjects with COPD exacerbations, defined as acute worsening of respiratory symptoms leading to additional treatment. Patients were divided randomly into two groups: 79 patients using beta-lactam antibiotics alone and 60 using beta-lactam antibiotics plus fluoroquinolones. Clinical and microbiological responses, spirometry tests, symptom scores, and serum C-reactive protein (CRP) levels were evaluated. RESULTS: Clinical success, lung function, and symptoms were similar in patients with or without fluoroquinolone administration on days 10 and 20. Combination therapy was superior in terms of microbiological outcomes and reduction in serum CRP value. Although equivalent to monotherapy in terms of clinical success, the combination showed superiority in terms of microbiological success and a decrease in CRP. The combination therapy group had a higher microbiological success rate with gram-negative bacteria than the monotherapy group with Pseudomonas aeruginosa (100% vs. 33.3%, respectively) and Acinetobacter baumanii (100% vs. 20%, respectively) (P < 0.05). CONCLUSIONS: Concomitant use of fluoroquinolone and beta-lactam antibiotics for bacterial infections during COPD exacerbations caused by gram-negative bacteria appear to be effective and should be applied in clinical practice.
format Online
Article
Text
id pubmed-8480084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84800842021-09-30 Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial Thu, Phuong Nguyen Thi Huong, Minh Ngo Thị Thi, Ngan Tran Thanh, Hoi Nguyen Minh, Khue Pham BMC Infect Dis Research BACKGROUND: The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbiological efficacy of antibiotics on day 20 of treatment, we conducted an open-label randomized trial based on clinical outcomes, microbiological clearance, spirometry tests, and signs of systemic inflammation in patients hospitalized with acute exacerbations of COPD. METHODS: We enrolled 139 subjects with COPD exacerbations, defined as acute worsening of respiratory symptoms leading to additional treatment. Patients were divided randomly into two groups: 79 patients using beta-lactam antibiotics alone and 60 using beta-lactam antibiotics plus fluoroquinolones. Clinical and microbiological responses, spirometry tests, symptom scores, and serum C-reactive protein (CRP) levels were evaluated. RESULTS: Clinical success, lung function, and symptoms were similar in patients with or without fluoroquinolone administration on days 10 and 20. Combination therapy was superior in terms of microbiological outcomes and reduction in serum CRP value. Although equivalent to monotherapy in terms of clinical success, the combination showed superiority in terms of microbiological success and a decrease in CRP. The combination therapy group had a higher microbiological success rate with gram-negative bacteria than the monotherapy group with Pseudomonas aeruginosa (100% vs. 33.3%, respectively) and Acinetobacter baumanii (100% vs. 20%, respectively) (P < 0.05). CONCLUSIONS: Concomitant use of fluoroquinolone and beta-lactam antibiotics for bacterial infections during COPD exacerbations caused by gram-negative bacteria appear to be effective and should be applied in clinical practice. BioMed Central 2021-09-29 /pmc/articles/PMC8480084/ /pubmed/34587911 http://dx.doi.org/10.1186/s12879-021-06687-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Thu, Phuong Nguyen Thi
Huong, Minh Ngo Thị
Thi, Ngan Tran
Thanh, Hoi Nguyen
Minh, Khue Pham
Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title_full Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title_fullStr Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title_full_unstemmed Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title_short Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
title_sort combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480084/
https://www.ncbi.nlm.nih.gov/pubmed/34587911
http://dx.doi.org/10.1186/s12879-021-06687-3
work_keys_str_mv AT thuphuongnguyenthi combinationantibiotictherapyversusmonotherapyinthetreatmentofacuteexacerbationsofchronicobstructivepulmonarydiseaseanopenlabelrandomizedtrial
AT huongminhngothi combinationantibiotictherapyversusmonotherapyinthetreatmentofacuteexacerbationsofchronicobstructivepulmonarydiseaseanopenlabelrandomizedtrial
AT thingantran combinationantibiotictherapyversusmonotherapyinthetreatmentofacuteexacerbationsofchronicobstructivepulmonarydiseaseanopenlabelrandomizedtrial
AT thanhhoinguyen combinationantibiotictherapyversusmonotherapyinthetreatmentofacuteexacerbationsofchronicobstructivepulmonarydiseaseanopenlabelrandomizedtrial
AT minhkhuepham combinationantibiotictherapyversusmonotherapyinthetreatmentofacuteexacerbationsofchronicobstructivepulmonarydiseaseanopenlabelrandomizedtrial